A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

Authors :: Salloway, S.
Sperling, R.
Keren, R.
Porsteinsson, A.P.
van Dyck, C.H.
Tariot, P.N.
Gilman, S.
Arnold, D.
Abushakra, S.
Hernandez, C.
Crans, G.
Liang, E.
Quinn, G.
Bairu, M.
Pastrak, A.
Cedarbaum, J.M.
Source :: Neurology (Ovid); September 2011, Vol. 77 Issue: 13 p1253-1262, 10p
Publication Year :: 2011
Abstract: This randomized, double-blind, placebo-controlled, dose-ranging phase 2 study explored safety, efficacy, and biomarker effects of ELND005 (an oral amyloid anti-aggregation agent) in mild to moderate Alzheimer disease (AD).

Full Text Access

Tools